Takeda Pharmaceutical Company Limited (TAK) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Takeda Pharmaceutical Company Limited  (NYSE: TAK)


Takeda Pharmaceutical Limited's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Takeda Pharmaceutical Limited's ROI in the fourth quarter of 2025?
Takeda Pharmaceutical Company Limited achieved a return on average invested assets (ROI) of 1.07 % in its fourth quarter of 2025, which is below Takeda Pharmaceutical Limited's average return on investment, which stands at 2.62%.

ROI fell compared to the third quarter of 2025, despite the net income growth of % from the third quarter of 2025.

Within the Healthcare sector 184 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 1943 to 2203.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Mar 31 2024)
IV. Quarter
Y / Y Investment Change TTM -4.94 % -0.88 % -1.54 % 2.66 % 3.24 %
Y / Y Net Income Change TTM -30.16 % -55.09 % -55.09 % -55.09 % -55.09 %
Investment (TTM) in Millions 62,099 69,144 62,099 64,199 69,144
Return On Investment (TTM) 1.07 % 1.49 % 1.51 % 1.47 % 1.46 %
TAK's Overall Ranking # 2203 # 1943 # # #
Seq. Investment Change TTM -2.66 % 1.53 % -2.63 % -1.2 % 1.49 %
Seq. Net Income Change TTM -30.16 % 0 % 0 % 0 % -55.09 %
Net Income (TTM) in Millions 689 986 986 986 986

TAK Company Profile >> Back to TAK Roi Comparisons >> See Annual TAK Return On Investment



Return On Investment TAK's Ranking
Within: No.
Industry # 62
Sector # 185
Overall # 2203

Return On Investment Statistics
High Average Low
4.81 %
2.62 %
1.11 %
(Mar 31 2021)   (Mar 31 2025)







Financial Statements
Takeda Pharmaceutical Limited's IV. Quarter Investments $ 62,099 Millions TAK's Balance sheet
Takeda Pharmaceutical Limited's IV. Quarter Income $ 689 Millions Quarterly TAK's Income Statement
TAK's Income by Division See TAK's Income by Division


TAK Annual Return On Investment (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2021
Total Investments in Millions 64,199 67,462 69,177 68,515 70,686
Y / Y Investment Growth -4.84 % -2.48 % 0.97 % -3.07 % 38.82 %
Net Income in Millions 710 999 2,345 2,050 3,549
Y / Y Net Income Growth -28.92 % -57.41 % 14.41 % -42.23 % 770.94 %
Annual Return On Investment 1.11 % 1.48 % 3.39 % 2.99 % 5.02 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 1.11 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TAK's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TAK's Competitors
Subscribers only: Roi for Takeda Pharmaceutical Limited's Suppliers
Subscribers only: Return On Investment for TAK's Customers

Other Ratios
TAK's Roa TAK's Inventory Turnover Ratio TAK's Growth Rates TAK's Dividend Statistics
TAK's Profitability Ratios TAK's Asset Turnover Ratio TAK's Dividend Growth
TAK's Roe TAK's Valuation Ratios TAK's Financial Strength Ratios TAK's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector ROI
Privia Health Group Inc   2.76 %
Penumbra Inc  2.69 %
Veracyte Inc   2.67 %
Integer Holdings Corporation  2.49 %
Perspective Therapeutics Inc   2.45 %
Talkspace Inc   2.45 %
Revvity Inc  2.39 %
Vaso Corporation  2.35 %
Adapthealth Corp   2.30 %
Pacs Group Inc   2.24 %
Teleflex Incorporated  2.17 %
Monte Rosa Therapeutics Inc   2.07 %
Bruker Corporation  1.73 %
Veru Inc   1.64 %
Amneal Pharmaceuticals Inc   1.43 %
Brightspring Health Services Inc   1.23 %
American Shared Hospital Services  1.04 %
Takeda Pharmaceutical Company Limited  0.97 %
Black Hawk Acquisition Corporation  0.92 %
Sotera Health Company  0.82 %
Vericel Corporation  0.82 %
Keros Therapeutics Inc   0.73 %
Incyte Corporation  0.58 %
Aveanna Healthcare Holdings Inc   0.42 %
Accuray Incorporated  0.23 %

Date modified: 2026-07-07T13:58:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.